3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Lymphoma
113
Leukemia
80
Precursor Cell Lymphoblastic Leukemia-Lymphoma
61
Lymphoma, Non-Hodgkin
59
Multiple Myeloma
56
Leukemia, Myeloid, Acute
56
Lymphoma, Large B-Cell, Diffuse
55
Hodgkin Disease
48
Myelodysplastic Syndromes
43
Burkitt Lymphoma
43
Lymphoma, Follicular
41
Leukemia, Lymphocytic, Chronic, B-Cell
41
Lymphoma, Mantle-Cell
40
Breast Neoplasms
35
Lymphoma, Large-Cell, Immunoblastic
34
Sarcoma
27
Neoplasms, Plasma Cell
27
Central Nervous System Neoplasms
25
Lymphoma, B-Cell, Marginal Zone
24
Dendritic Cell Sarcoma, Interdigitating
19
Recurrence
18
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18
Ovarian Neoplasms
16
Neuroblastoma
16
Myeloproliferative Disorders
16
Leukemia, Myeloid, Chronic-Phase
16
Leukemia, Myeloid, Accelerated Phase
15
Congenital Abnormalities
15
Neutropenia
13
Lung Neoplasms
13
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Congenital Bone Marrow Failure Syndromes
×
Filgrastim
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled